Anticoagulants

Slide 1 · Anticoagulants

Drug-related bleeding · coagulation targets · clinicopathologic assessment

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Teaching objectives

Explain why suppression of coagulation prevents thrombosis but can produce hemorrhage.

Locate the actions of warfarin, dabigatran, factor Xa inhibitors, and heparin.

Compare source-described benefits and limitations of oral anticoagulant classes.

Apply hemostasis and bleeding-disorder principles to clinical interpretation.

Slide 3 · Where anticoagulants fit in drug injury

Adverse drug reactions are unwanted effects occurring at prescribed drug doses.

An intended pharmacologic action may create an undesirable tissue-level outcome.

For anticoagulants, impaired clot formation can translate into uncontrolled hemorrhage.

The pathology question is a shifted balance between thrombosis and bleeding.

Slide 4 · Therapeutic benefit versus adverse effect

Desired effect

Reduce formation or extension of thrombi

Prevent thromboembolic events

Interrupt selected reactions of secondary hemostasis

Principal hazard

Reduced ability to arrest bleeding

Hemorrhage after vascular injury or trauma

Potentially severe or fatal blood loss

Slide 5 · Vascular injury initiates normal hemostasis

Transient vasoconstriction

Platelet adhesion and activation

Thrombin generation

Fibrin-stabilized plug

A sequence, not four independent responses.

Anticoagulants chiefly interfere with the coagulation component.

Slide 6 · Primary hemostasis forms the platelet plug

Exposed collagen and von Willebrand factor facilitate platelet adhesion.

Adherent platelets change shape, release granules, and recruit neighbors.

Fibrinogen bridges activated platelet GpIIb/IIIa receptors.

This initial plug requires later reinforcement by fibrin.

Slide 7 · Secondary hemostasis strengthens the plug

Tissue factor exposure

Activation of coagulation proteases

Generation of thrombin

Fibrin deposition

Failure to generate adequate fibrin makes the hemostatic seal less durable.

Slide 8 · Tissue factor initiates coagulation in vivo

Tissue factor normally resides beyond intact endothelium.

Vessel disruption exposes tissue factor to circulating blood.

Tissue factor–factor VIIa activity initiates the coagulation cascade.

Laboratory intrinsic/extrinsic pathways simplify a more integrated in vivo system.

Slide 9 · A central coagulation sequence

Factor X

Factor Xa

Prothrombin (factor II) → thrombin (IIa)

Fibrinogen → fibrin

Xa and thrombin are direct oral anticoagulant targets.

This pathway is a focused schematic, not the entire cascade.

Slide 10 · Factor Xa is an amplification junction

Activated factor X participates in the prothrombinase complex.

Factor Va accelerates conversion of prothrombin into thrombin.

Calcium and a platelet phospholipid surface support complex assembly.

Direct inhibition of Xa interrupts downstream thrombin generation.

Slide 11 · Thrombin has more than one hemostatic role

Thrombin converts soluble fibrinogen into insoluble fibrin.

It activates factor XIII, supporting fibrin cross-linking.

It activates platelets and additional coagulation reactions.

Blocking thrombin affects the production and stabilization of a fibrin clot.

Slide 12 · Activated platelets provide a reaction surface

Activation externalizes negatively charged phospholipids.

Coagulation complexes assemble on these phospholipid surfaces.

Calcium links components within the complexes.

This spatial localization helps keep coagulation concentrated at injury sites.

Slide 13 · Clot formation is balanced by clot restriction

Local procoagulant response

Tissue factor initiates coagulation

Thrombin produces a fibrin network

Platelets reinforce the local plug

Counter-regulatory response

Intact endothelium suppresses clot spread

Antithrombin and protein C inhibit coagulation

Plasmin participates in clot resorption

Slide 14 · Intact endothelium opposes clotting

Normal endothelium separates blood from subendothelial tissue factor.

Thrombomodulin and endothelial protein C receptor redirect thrombin activity.

Heparin-like molecules facilitate antithrombin activity.

Tissue factor pathway inhibitor limits tissue factor–VIIa reactions.

Slide 15 · Protein C and protein S suppress amplification

Thrombin bound to thrombomodulin

Activation of protein C

Activated protein C + protein S

Inhibition of factors Va and VIIIa

A physiologic anticoagulant mechanism differs from direct drug inhibition.

Slide 16 · Antithrombin targets active proteases

Endothelial heparin-like molecules

Augmented antithrombin activity

Inhibition of thrombin, Xa and other proteases

Heparin and related drugs exploit this endogenous inhibitory pathway.

Slide 17 · Coagulation and fibrinolysis are distinct

Coagulation deposits fibrin to reinforce the hemostatic plug.

Tissue plasminogen activator helps generate plasmin.

Plasmin degrades fibrin during clot resorption.

An anticoagulant suppresses clot formation; A fibrinolytic promotes clot breakdown.

Slide 18 · Natural versus pharmacologic anticoagulation

Physiologic controls

Thrombomodulin–protein C system

Antithrombin plus endothelial heparin-like molecules

Tissue factor pathway inhibitor

Drug interventions

Warfarin: Vitamin K antagonism

Dabigatran: Direct thrombin inhibition

Apixaban/rivaroxaban: Factor Xa inhibition

Slide 19 · Oral anticoagulants: Classes named by Robbins

Vitamin K antagonist: Warfarin.

Direct thrombin inhibitor: Dabigatran.

Direct factor Xa inhibitors: Apixaban and rivaroxaban.

Direct thrombin and factor Xa inhibitors are grouped as DOACs.

Slide 20 · Class comparison: Action and examples

Class

Examples

Primary target

Vitamin K antagonist

Warfarin

Vitamin K–dependent factor maturation

Direct thrombin inhibitor

Dabigatran

Thrombin (IIa)

Direct factor Xa inhibitors

Apixaban, rivaroxaban

Activated factor X (Xa)

Slide 21 · Vitamin K supports factor function

Vitamin K–dependent γ-carboxylation

Factors II, VII, IX, X gain Ca²⁺ binding sites

Factors assemble on phospholipid surfaces

Efficient clotting reactions

Warfarin antagonizes the vitamin K-dependent step.

Slide 22 · Warfarin acts upstream of several factors

Warfarin as a vitamin K antagonist.

Vitamin K participates in modification of factors II, VII, IX, and X.

Antagonism disrupts normal function of these vitamin K-dependent proteins.

Its effect therefore differs from blocking a single active protease.

Slide 23 · Warfarin is vulnerable to interactions

Many drugs interfere with warfarin metabolism.

Vitamin K-rich foods can oppose its pharmacologic effect.

Changes in either exposure can alter the achieved anticoagulation.

Diet and medication history are central to interpretation.

Slide 24 · Why warfarin needs repeated blood testing

The level of anticoagulation may vary with interacting medications and diet.

Regular blood sampling for monitoring.

Maintaining anticoagulation within a safe therapeutic range can be difficult.

This monitoring burden is a key disadvantage relative to DOACs.

Slide 25 · Warfarin: Cost advantage and trade-offs

Warfarin is inexpensive according to the source passage.

Medication and vitamin K interactions complicate management.

Regular monitoring adds practical burden.

Low acquisition cost does not alone determine overall value.

Slide 26 · Direct thrombin inhibition

Dabigatran

Inhibition of thrombin activity

Reduced conversion of fibrinogen to fibrin

Attenuated secondary hemostasis

The antithrombotic effect and bleeding liability arise from the same target.

Slide 27 · Direct factor Xa inhibition

Apixaban or rivaroxaban

Inhibition of factor Xa

Less Xa-driven prothrombin activation

Reduced thrombin and fibrin generation

Target distinction: Xa inhibitors act upstream of thrombin.

Slide 28 · Dabigatran versus factor Xa inhibitors

Dabigatran

Directly inhibits thrombin (IIa)

Interferes with final fibrin generation

A named direct oral anticoagulant

Apixaban / rivaroxaban

Directly inhibit factor Xa

Limit conversion of prothrombin to thrombin

Named direct oral anticoagulants

Slide 29 · Why DOACs simplify routine treatment

Compared with warfarin, fewer food and drug interactions.

Use in fixed doses is feasible in the settings described.

Routine monitoring is not required for most recipients.

These advantages do not remove bleeding risk or all treatment constraints.

Slide 30 · Monitoring burden: Warfarin and DOACs

Warfarin

Influenced by interacting drugs

Vitamin K intake affects activity

Regular blood-sampling surveillance

DOACs

Fewer interaction-related complications described

Fixed-dose use in appropriate patients

No routine anticoagulant monitoring

Slide 31 · Comparative efficacy: What the source claims

Favorable efficacy profiles for DOACs versus warfarin.

Its comparison concerns chronic oral anticoagulation in broad populations.

It is not a claim of superiority in every individual or indication.

No trial-specific relative risks or pooled effect sizes are supplied here.

Slide 32 · Comparative safety: Interpret carefully

The source reports favorable safety profiles for DOACs.

Both drug classes can still cause uncontrolled bleeding.

A favorable average safety profile does not mean absence of hemorrhage.

Patient selection and clinical circumstances remain essential.

Slide 33 · Mortality benefit: Level of detail

The source states that DOACs result in lower mortality than warfarin.

No absolute risk, study denominator, or specific trial is provided in the extracted section.

Avoid converting this textbook summary into an invented quantitative claim.

Clinical applicability remains dependent on the patient group.

Slide 34 · Reversal changes the bleeding-risk equation

The source states that reversal agents have improved DOAC safety.

Rapid reversal addresses the anticoagulant contribution to dangerous bleeding.

It does not automatically correct the underlying bleeding source.

Specific antidote selection and protocols are outside this excerpt.

Slide 35 · Direct drug cost versus total clinical cost

Acquisition expense

Warfarin is relatively inexpensive

DOACs have higher drug prices

Upfront cost is only one component

Broader cost consequence

Bleeding events carry clinical costs

Stroke prevention alters downstream burden

Textbook cites studies suggesting DOAC cost-effectiveness

Slide 36 · Why DOACs are often preferred

Favorable source-described efficacy and safety compared with warfarin.

Convenience of fixed dosing without routine monitoring.

Reduced food and medication interaction burden.

DOACs as preferred for many—not all—patients needing chronic therapy.

Slide 37 · Patient groups needing separate judgment

Atrial fibrillation with valve abnormalities as an exception.

Advanced kidney or liver disease is another stated exception.

These are signals for individualized selection, not comprehensive prescribing criteria.

This lecture does not infer drug-specific eligibility thresholds from the excerpt.

Slide 38 · Core oral anticoagulant trade-offs

Domain

Warfarin

DOACs

Mode of action

Vitamin K antagonist

Direct IIa or Xa inhibition

Routine monitoring

Regular blood sampling

Not generally required

Food/drug interactions

Major practical limitation

Fewer in source description

Acquisition cost

Lower

Higher

Slide 39 · Bleeding is an on-target adverse reaction

The intended pharmacologic effect is reduced clot formation.

That same effect impairs containment of vascular injury.

Bleeding may emerge under hemostatic stress, especially after trauma.

An adverse outcome need not reflect an incorrect prescription.

Slide 40 · Why trauma magnifies hemorrhage

Vessel disruption

Need for rapid thrombin and fibrin formation

Anticoagulant suppression of the response

More prolonged or uncontrolled bleeding

Robbins specifically highlights bleeding after trauma.

Slide 41 · Hemorrhagic injury: What determines severity

Amount of blood lost is important.

Rate of bleeding influences hemodynamic impact.

Site matters: Confined compartments are especially consequential.

Anticoagulant exposure adds to, rather than replaces, these determinants.

Slide 42 · Intracranial bleeding is anatomically hazardous

The skull cannot expand substantially as hemorrhage accumulates.

Raised intracranial pressure can compromise perfusion.

Severe mass effect can precipitate herniation.

A comparatively small bleed may be devastating because of its location.

Slide 43 · Rapid blood loss can produce shock

Large-volume acute hemorrhage depletes circulating volume.

Systemic hypoperfusion can follow severe losses.

Anticoagulants may aggravate ongoing bleeding if hemostasis is impaired.

Clinical urgency depends on physiology, not merely visible blood.

Slide 44 · Recurrent external bleeding depletes iron

Repeated loss of blood removes iron from the body.

Persistent gastrointestinal or menstrual blood loss can cause iron deficiency.

Blood confined to tissues may permit recovery and recycling of iron.

Bleeding duration and site influence hematologic consequences.

Slide 45 · Bleeding patterns help localize the defect

Primary hemostasis defects

Petechiae and purpura

Skin and mucosal bleeding

Epistaxis and menorrhagia

Secondary hemostasis defects

Muscular and deep-tissue bleeds

Joint hemorrhage in severe factor defects

Potential intracranial hemorrhage

Slide 46 · Why clinical pattern is not diagnostic alone

Petechiae may reflect platelet or vessel-wall disease.

Deep bleeding suggests a coagulation-factor problem but is not specific.

Patients can have several overlapping contributors.

Exposure history and targeted testing are needed for interpretation.

Slide 47 · A structured bleeding assessment

Identify site, rate and severity

Review anticoagulant exposure and trauma

Assess platelets and coagulation

Interpret findings in clinical context

Diagnostic reasoning schematic; Not a treatment protocol.

Slide 48 · PT examines extrinsic and common pathways

Prothrombin time evaluates a laboratory clotting reaction.

It is sensitive to abnormalities involving VII, X, V, II, or fibrinogen.

The assay adds tissue-factor activity and calcium to plasma.

It is a pathway assay—not a complete simulation of in vivo hemostasis.

Slide 49 · PTT examines intrinsic and common pathways

Partial thromboplastin time measures a contact-initiated laboratory reaction.

Defects in VIII, IX, XI, XII and common-pathway factors can prolong it.

Interfering antiphospholipid antibodies may also prolong PTT.

A prolonged assay has more than one possible explanation.

Slide 50 · PT versus PTT: Conceptual comparison

Property

PT

PTT

Pathway emphasized

Extrinsic + common

Intrinsic + common

Initiating components

Tissue factor + calcium

Contact activator + phospholipid + calcium

Representative factors

VII, X, V, II, fibrinogen

VIII, IX, XI, XII; Common factors

Slide 51 · Platelet count addresses a different mechanism

Platelet enumeration tests a component of primary hemostasis.

Automated low counts may reflect platelet clumping rather than true loss.

Peripheral blood smear review helps recognize pseudothrombocytopenia.

An anticoagulant effect cannot be inferred from platelet count alone.

Slide 52 · The limitations of routine coagulation assays

PT and PTT reflect reagent-driven laboratory pathways.

They do not recreate all of the spatial and endothelial controls of hemostasis.

Abnormal results need a differential diagnosis.

A normal screening assay does not assess every possible hemostatic abnormality.

Slide 53 · Anticoagulant effect versus thrombocytopenia

Coagulation inhibition

Fibrin generation or maturation affected

Oral agents target vitamin K, thrombin, or Xa

Bleeding is an expected class hazard

Reduced platelet count

Fewer platelets for a primary plug

Multiple causes including immune destruction

Heparin can cause immune platelet activation with thrombosis

Slide 54 · Heparin uses endogenous antithrombin

Heparin-related drugs increase antithrombin activity.

Antithrombin inhibits thrombin and several activated factors, including Xa.

This differs from direct binding to IIa or Xa by a DOAC.

The same hemostatic context explains anticoagulant bleeding liability.

Slide 55 · Heparin-associated thrombocytopenia: Two forms

Type I: Early, generally minor, can resolve during continued treatment.

Type II: Immune-mediated and potentially life-threatening.

Type II is associated with both falling platelets and thrombosis.

Do not conflate thrombocytopenia with protection from clotting.

Slide 56 · Immune HIT: Mechanistic sequence

Heparin binds platelet factor 4

Antibodies recognize PF4–heparin complexes

Platelet Fc-receptor activation

Prothrombotic platelet response

A drug-related immunologic injury, not simply excessive anticoagulation.

Slide 57 · Why HIT can cause thrombosis despite low platelets

Antibody-mediated platelet activation promotes coagulation.

Activated platelets release procoagulant signals.

Macrophage-mediated platelet removal contributes to thrombocytopenia.

The clinically dangerous phenotype may be venous or arterial thrombosis.

Slide 58 · Clues to type II HIT

Onset typically days after heparin initiation.

Prior heparin sensitization may change the timing.

New thrombosis and a falling platelet count are concerning together.

The source identifies anti-PF4/heparin antibodies as a diagnostic component.

Slide 59 · Why low-molecular-weight heparin is not a rescue for HIT

Before immune HIT

Lower risk of type II HIT than unfractionated heparin

Risk is reduced, not abolished

Exposure can still be relevant

After type II HIT develops

Heparin products worsen the prothrombotic state

Low-molecular-weight heparin must also be avoided

Textbook specifies a nonheparin alternative

Slide 60 · HIT belongs to a different adverse-effect category

Ordinary anticoagulant bleeding arises from impaired hemostatic clot formation.

Immune HIT arises from antibodies and platelet activation.

HIT may produce limb ischemia, venous thromboembolism, or other thromboses.

Differentiating mechanisms changes clinical interpretation.

Slide 61 · Case 1 · Altered oral anticoagulant response

An individual taking warfarin changes several medications and markedly alters dietary vitamin K intake. They are then found to have unexpected bleeding.

Which pharmacologic property complicates warfarin management?

Which source-described feature makes sustained control challenging?

Slide 62 · Case 1 · Mechanistic interpretation

Warfarin activity is sensitive to medications and vitamin K intake.

Its anticoagulant effect therefore requires regular surveillance.

Uncontrolled bleeding is consistent with excess pharmacologic anticoagulation.

The case does not permit a specific test value or cause to be asserted.

Slide 63 · Case 2 · Selecting a drug mechanism

A patient is prescribed rivaroxaban for chronic anticoagulation. An educator asks which step of the cascade is affected directly.

Does rivaroxaban block thrombin or factor Xa?

How does this change downstream fibrin formation?

Slide 64 · Case 2 · Follow the pathway

Rivaroxaban directly inhibits factor Xa.

Factor Xa normally helps convert prothrombin to thrombin.

Reduced thrombin generation reduces conversion of fibrinogen into fibrin.

The benefit and bleeding risk share this causal chain.

Slide 65 · Case 3 · Low platelet count with new thrombosis

Several days after starting heparin, a patient develops a platelet-count fall and new arterial thrombosis.

Why is thrombosis possible despite thrombocytopenia?

What immune target is central to this syndrome?

Slide 66 · Case 3 · Distinguish HIT from excess dosing

Antibodies against PF4–heparin complexes activate platelets.

Platelet activation generates a prothrombotic state.

Platelet clearance simultaneously contributes to thrombocytopenia.

This pattern calls for recognition of immune HIT, not a dose-only explanation.

Slide 67 · Two different drug-related adverse mechanisms

Expected anticoagulant effect

Coagulation activity is suppressed

A stable plug may fail to develop

Uncontrolled bleeding may follow

Immune heparin reaction

PF4–heparin antibodies activate platelets

Immune platelet clearance lowers the count

Thrombosis may occur despite thrombocytopenia

Slide 68 · Integrated comparison: Three mechanistic themes

Reduction of coagulation

Warfarin: Factor maturation

Dabigatran: Thrombin

Apixaban/rivaroxaban: Xa

Pathologic consequences

Bleeding when a stable plug cannot form

Severity depends on rate and site

HIT is a separate immune thrombotic complication

Slide 69 · Core clinicopathologic conclusions

Anticoagulants trade reduced thrombosis for a bleeding hazard.

Warfarin and DOACs interrupt coagulation at different steps.

Practical advantages of DOACs but explicit exceptions remain.

Bleeding phenotype, severity and laboratory tests require integrated assessment.

Immune HIT is a thrombotic adverse reaction to heparin.

Slide 70 · Source and teaching boundaries

Primary anchor: Robbins, Cotran & Kumar, 11th ed., Ch. 9, pp. 383–384.

Mechanistic context: Ch. 4, hemostasis, hemorrhagic disorders, and HIT.

Laboratory context: Ch. 14, bleeding disorders and coagulation assays.

Treatment algorithms, drug-specific dosing, and updated society recommendations are not supplied in these excerpts.